Adil Javed

Neurology Chicago, IL Male
NPI: 1932142833
Total Payments
$1.0M
2024 Payments
$20,848
Companies
21
Transactions
1,109
Medicare Patients
1,296
Medicare Billing
$135,272

Payment Breakdown by Category

Other$710,818 (68.4%)
Consulting$250,705 (24.1%)
Travel$41,341 (4.0%)
Food & Beverage$35,618 (3.4%)
Education$650.22 (0.1%)
Research$148.14 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $699,518 266 67.3%
Consulting Fee $250,705 63 24.1%
Travel and Lodging $41,341 116 4.0%
Food and Beverage $35,618 652 3.4%
Honoraria $11,300 4 1.1%
Education $650.22 7 0.1%
Unspecified $148.14 1 0.0%

Payments by Type

General
$1.0M
1,108 transactions
Research
$148.14
1 transactions

Top Paying Companies

Company Total Records Latest Year
GENZYME CORPORATION $330,664 265 $0 (2024)
Biogen, Inc. $204,799 189 $0 (2023)
Genentech USA, Inc. $141,654 99 $0 (2024)
Novartis Pharmaceuticals Corporation $120,718 151 $0 (2024)
Celgene Corporation $69,173 80 $0 (2024)
EMD Serono, Inc. $45,140 146 $0 (2024)
Alexion Pharmaceuticals, Inc. $33,950 35 $0 (2023)
Horizon Therapeutics plc $26,533 25 $0 (2023)
TG Therapeutics, Inc. $25,824 36 $0 (2024)
E.R. Squibb & Sons, L.L.C. $15,360 16 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $20,848 47 Novartis Pharmaceuticals Corporation ($6,773)
2023 $69,981 82 Biogen, Inc. ($17,462)
2022 $77,032 86 Biogen, Inc. ($31,853)
2021 $71,305 69 Horizon Therapeutics plc ($21,250)
2020 $116,366 91 Celgene Corporation ($25,756)
2019 $197,068 239 GENZYME CORPORATION ($39,483)
2018 $247,470 254 GENZYME CORPORATION ($144,821)
2017 $239,209 241 GENZYME CORPORATION ($105,159)

All Payment Transactions

1,109 individual payment records from CMS Open Payments — Page 1 of 45

Date Company Product Nature Form Amount Type
12/19/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $143.96 General
11/19/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Food and Beverage In-kind items and services $76.20 General
Category: Neurology
11/15/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Consulting Fee Cash or cash equivalent $5,300.00 General
Category: Neurology
11/15/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Travel and Lodging In-kind items and services $884.96 General
Category: Neurology
11/15/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Travel and Lodging In-kind items and services $242.02 General
Category: Neurology
11/15/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Food and Beverage In-kind items and services $152.84 General
Category: Neurology
11/13/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $36.06 General
Category: Immunology
11/13/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $14.03 General
Category: Neuroscience
11/12/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $930.00 General
Category: Immunology
11/12/2024 NOBELPHARMA AMERICA, LLC HYFTOR (Drug) Food and Beverage In-kind items and services $117.80 General
Category: Dermatology
11/11/2024 EMD Serono, Inc. — Food and Beverage Cash or cash equivalent $50.88 General
10/30/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $18.26 General
Category: Neuroscience
10/23/2024 EMD Serono, Inc. Mavenclad (Drug) Food and Beverage Cash or cash equivalent $153.78 General
Category: Neurology
09/19/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $132.35 General
Category: Immunology
09/17/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $76.47 General
Category: Immunology
09/10/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Food and Beverage In-kind items and services $12.63 General
Category: Neurology
09/03/2024 EMD Serono, Inc. — Food and Beverage Cash or cash equivalent $51.61 General
08/15/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $117.67 General
08/11/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $15.64 General
Category: Immunology
07/23/2024 Novartis Pharmaceuticals Corporation KESIMPTA (Drug) Food and Beverage In-kind items and services $80.72 General
Category: Neurology
07/12/2024 EMD Serono, Inc. — Food and Beverage Cash or cash equivalent $29.24 General
07/03/2024 EMD Serono, Inc. — Food and Beverage Cash or cash equivalent $56.61 General
05/30/2024 EMD Serono, Inc. — Food and Beverage Cash or cash equivalent $93.55 General
05/30/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $49.18 General
Category: Immunology
05/30/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $14.96 General
Category: Immunology
123…45»

Research Studies & Clinical Trials

Study Name Company Amount Records
SA307 F. Hoffmann-La Roche AG $148.14 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 296 369 $159,457 $31,329
2022 6 308 391 $154,719 $33,685
2021 8 355 473 $175,285 $37,064
2020 9 337 487 $168,608 $33,193
Total Patients
1,296
Total Services
1,720
Medicare Billing
$135,272
Procedure Codes
34

All Medicare Procedures & Services

34 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 138 179 $63,104 $13,186 20.9%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 65 96 $40,804 $8,829 21.6%
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes Facility 2023 30 30 $24,560 $3,276 13.3%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 24 24 $13,820 $2,516 18.2%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 11 11 $9,613 $1,893 19.7%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 15 16 $3,824 $882.23 23.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 13 13 $3,732 $747.64 20.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 123 158 $53,834 $11,939 22.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 66 97 $39,858 $8,798 22.1%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2022 34 34 $18,784 $3,978 21.2%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 13 13 $10,404 $2,338 22.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 16 16 $8,512 $2,023 23.8%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 31 34 $8,087 $1,670 20.7%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 13 27 $7,590 $1,582 20.8%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 12 12 $7,650 $1,356 17.7%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 152 198 $65,448 $14,600 22.3%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 40 52 $20,649 $4,622 22.4%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 19 71 $18,891 $4,400 23.3%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 33 33 $25,803 $3,801 14.7%
99204 New patient outpatient visit, total time 45-59 minutes Facility 2021 32 32 $17,333 $3,430 19.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 20 23 $8,897 $2,046 23.0%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 29 33 $7,393 $1,771 24.0%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 14 14 $7,286 $1,564 21.5%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Facility 2021 16 17 $3,585 $830.62 23.2%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 171 237 $79,104 $14,346 18.1%
12»

About Adil Javed

Adil Javed is a Neurology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932142833.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Adil Javed has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $20,848 received in 2024. These payments were reported across 1,109 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($699,518).

As a Medicare-enrolled provider, Javed has provided services to 1,296 Medicare beneficiaries, totaling 1,720 services with total Medicare billing of $135,272. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.

Practice Information

  • Specialty Neurology
  • Location Chicago, IL
  • Active Since 06/14/2006
  • Last Updated 10/24/2022
  • Taxonomy Code 2084N0400X
  • Entity Type Individual
  • NPI Number 1932142833

Products in Payments

  • AUBAGIO (Drug) $180,738
  • LEMTRADA (Drug) $115,404
  • GILENYA (Drug) $66,118
  • OCREVUS (Biological) $61,137
  • ZEPOSIA (Drug) $54,008
  • TYSABRI (Biological) $43,945
  • TECFIDERA (Drug) $43,810
  • Non-Covered Product (Drug) $40,939
  • Enspryng (Biological) $30,840
  • Ozanimod (Drug) $30,178
  • VUMERITY (Drug) $27,447
  • UPLIZNA (Drug) $26,533
  • BRIUMVI (Drug) $22,862
  • Mavenclad (Drug) $16,244
  • MAYZENT (Drug) $14,942
  • Ocrevus (Biological) $14,453
  • Mavenclad (Biological) $11,627
  • PLEGRIDY (Biological) $9,917
  • KESIMPTA (Drug) $7,600
  • ARZERRA (Drug) $7,263

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Neurology Doctors in Chicago

Mr. Augusto Miravalle, Md, MD

Neurology — Payments: $1.1M

Neurology $1.1M

Douglas Nordli, Md, MD

Neurology — Payments: $654,190

Neurology $654,190

Dr. Dusan Stefoski, Md, MD

Neurology — Payments: $610,165

Neurology $610,165

Dr. Danny Bega, M.d, M.D

Neurology — Payments: $432,383

Neurology $432,383

Tatyana Simuni, Md, MD

Neurology — Payments: $385,696

Neurology $385,696

Dr. Michael Smith, Md, MD

Neurology — Payments: $365,989

Neurology $365,989